March 28, 2018 / 8:20 PM / in 7 months

BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase

March 28 (Reuters) - Biomarin Pharmaceutical Inc:

* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARIN’S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)

* BIOMARIN PHARMACEUTICAL INC - FDA PDUFA ACTION DATE FOR PEGVALIASE IS MAY 25, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below